PDCD1 and nonpapillary renal cell carcinoma: A Phase 3 LITESPARK-005 (NCT04195750), an open-label, randomized, head-to-head trial was performed with 746 patients having unresectable locally advanced or metastatic ccRCC that had progressed following a programmed death receptor-1 (PD-1) or programmed death-ligand 1 (PD-L1) checkpoint inhibitor and a VEGF–tyrosine kinase inhibitor (TKI).